Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exscientia Ltd ADR (NQ: EXAI )

5.292 +0.052 (+0.99%)
Streaming Delayed Price Updated: 9:54 AM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exscientia Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
From Exscientia plc
Via Business Wire
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Exscientia Business and Financial Update for the Third Quarter 2022
From Exscientia plc
Via Business Wire
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
From Exscientia plc
Via Business Wire
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
From Exscientia plc
Via Business Wire
Exscientia Expands Biologics Design Capability with Automated Laboratory
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in November
From Exscientia
Via Business Wire
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
From Exscientia plc
Via Business Wire
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
From Exscientia plc
Via Business Wire
Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes
From Exscientia
Via Business Wire
Exscientia Welcomes Caroline Rowland as Chief People Officer
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in September
From Exscientia
Via Business Wire
Exscientia Business Update for Second Quarter and First Half 2022
From Exscientia plc
Via Business Wire
Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022
From Exscientia
Via Business Wire
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
From Exscientia plc
Via Business Wire
Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
From Exscientia
Via Business Wire
Exscientia Business Update for First Quarter 2022
From Exscientia plc
Via Business Wire
Exscientia to Report First Quarter 2022 Financial Results on May 25, 2022
From Exscientia
Via Business Wire
Exscientia to Present at the BofA Securities 2022 Healthcare Conference
From Exscientia
Via Business Wire
Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022
From Exscientia plc
Via Business Wire
Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer
From Exscientia
Via Business Wire
Exscientia Business Update for Fourth Quarter and Full Year 2021
From Exscientia plc
Via Business Wire
Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022
From Exscientia
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in March
From Exscientia
Via Business Wire
Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
From Exscientia
Via Business Wire
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
From Exscientia
Via Business Wire
Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
From Exscientia
Via Business Wire
Exscientia Business Update for Third Quarter 2021
From Exscientia
Via Business Wire
Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021
From Exscientia
Via Business Wire
Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes
From Exscientia
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.